Industry News
Market moves: CSL buyback hits $600m
CSL (ASX:CSL) has now repurchased close to $600 million worth of its own shares, under a buyback program which commenced in October last year. [ + ]
Mayne clears hurdle to SUBACAP approval in EU
Mayne Pharma (ASX:MYX) is back on track to gaining marketing approval from the EMA for its SUBACAP fungal infection treatment, after its application was temporarily derailed by UK regulators. [ + ]
World’s top agbiotech conference to visit Down Under
The world’s leading agricultural biotechnology event, ABIC (Agricultural Biotechnology International Conference) 2012, is coming to our region in September with the annual event to be held in Rotorua, New Zealand, and hosted by NZBIO with the support of AusBiotech. [ + ]
Virus traces in Fluvax blamed for risk in children
CSL (ASX:CSL) unit CSL Biotherapies has tentatively blamed the particulars of the manufacturing process for the adverse reactions to its Fluvax influenza vaccine in some young children in 2010. [ + ]
Awards support the future of agricultural science
Dr Matt Cahill, Dow AgroSciences Research and Development Leader for Australia and New Zealand, and the Hon Sid Sidebottom, Parliamentary Secretary for Agriculture, Fisheries and Forestry, have recognised the work of promising students and inspirational teachers in the primary industries sector with the presentation of annual awards. [ + ]
Stem cell research gains momentum in Queensland
Stem Cells Ltd, based at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland, is set to receive $470,000 in Queensland Government science funding to advance cutting-edge stem cell research into diseases such as schizophrenia, Down syndrome, Parkinson’s disease and heart disease. [ + ]
BIO 2012 biotech profile: Bionomics
Bionomics recently captured headlines with its spectacular deal with Ironwood Pharmaceuticals for its anti-anxiety compound, BNC210. But the South Australian biotech has even more tricks up its sleeve. [ + ]
Mesoblast insists Teva partnership is strong
Mesoblast (ASX:MSB) has defended the strength of its relationship with key partner Teva Pharmaceutical Industries, calling rumors that Teva is not committed to the tie-up “unfounded.” [ + ]
Immuron raises $442k in undersubscribed SPP
Immuron (ASX:IMC) has raised just over $442,000 in a share purchase plan (SPP), less than half of the $1 million target. [ + ]
R&D Tax Incentive attracts MS clinical trial
New Zealand-based Innate Immunotherapeutics has announced the company will proceed with plans to conduct a Phase IIB clinical trial in Australia, after positive interim data from the company’s Phase I/II clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS). [ + ]
International Nanomedicine Conference bound for Sydney
The Australian Centre for Nanomedicine at the University of New South Wales will host the third International Nanomedicine Conference from 2-4 July at the Crowne Plaza Coogee Beach, Sydney. [ + ]
BIO 2012: Australian biotechnology’s time to shine
The second wave of Australian biotechnology companies is on the cusp of breaking out, but a new phenomenon is emerging in the life sciences industry: a three-tier economy. [ + ]
CSIRO’s WLAN technology wins international award
Australian science has been recognised as among the world’s best after the Minister for Science and Research, Senator Chris Evans, announced that the CSIRO inventors behind the WLAN technology have won the European Inventors Award. [ + ]
Magnetic resonance imaging pioneer honoured
UniQuest has congratulated The University of Queensland’s (UQ) Professor Stuart Crozier on receiving a 2012 Academy of Technology and Engineering Sciences (ATSE) Clunies Ross Award for his 20-year commitment to the field of magnetic resonance imaging (MRI). [ + ]
The Australian Innovation Challenge hunts for the nation’s best ideas
The search is on again for the nation’s greatest ideas - in fields from environmental science to education - through the $70,000 The Australian Innovation Challenge awards. [ + ]